3,175 Shares in Revolution Medicines, Inc. $RVMD Acquired by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, HoldingsChannel reports. The fund bought 3,175 shares of the company’s stock, valued at approximately $595,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its stake in shares of Revolution Medicines by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock worth $980,036,000 after purchasing an additional 947,448 shares in the last quarter. Nextech Invest Ltd. raised its stake in shares of Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Paradigm Biocapital Advisors LP raised its stake in shares of Revolution Medicines by 6.8% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company’s stock valued at $529,227,000 after purchasing an additional 421,112 shares in the last quarter. Bellevue Group AG lifted its holdings in Revolution Medicines by 21.7% in the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock worth $260,298,000 after purchasing an additional 994,538 shares during the period. Finally, Deerfield Management Company L.P. lifted its holdings in Revolution Medicines by 7.9% in the third quarter. Deerfield Management Company L.P. now owns 3,650,342 shares of the company’s stock worth $170,471,000 after purchasing an additional 266,270 shares during the period. Institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling

In related news, CFO Jack Anders sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares in the company, valued at $20,749,870.77. The trade was a 13.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Margaret A. Horn sold 60,400 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the sale, the chief operating officer directly owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is owned by insiders.

Analyst Ratings Changes

RVMD has been the topic of several research analyst reports. Sanford C. Bernstein raised their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research note on Friday, August 21st. Wedbush upped their price target on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. UBS Group increased their price objective on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright raised their price objective on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Needham & Company LLC boosted their target price on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Revolution Medicines has a consensus rating of “Moderate Buy” and a consensus price target of $200.74.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $205.57 on Tuesday. The business’s 50-day moving average price is $194.12 and its 200 day moving average price is $149.73. The firm has a market cap of $44.06 billion, a P/E ratio of -23.31 and a beta of 1.39. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the previous year, the company posted ($1.31) EPS. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -8.85 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.